On February 13, 2025, Prostatype Genomics AB (the "Company") disclosed its annual financial statement release for 2024 with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that an issuer can be given observation status if there is material adverse uncertainty in respect of the issuer's financial position.
With reference to the above, Nasdaq Stockholm AB decides that the shares in Prostatype Genomics AB (PROGEN, ISIN code SE0023261532, order book ID 207035) shall be given observation status.
For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.
Nasdaq Stockholm AB
© 2025 GlobeNewswire
